이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Heart Test Laboratories 관리

관리 기준 확인 4/4

Heart Test Laboratories' CEO는 Andrew Simpson, Mar2022 에 임명되었습니다 의 임기는 2.25 년입니다. 총 연간 보상은 $ 455.94K, 51.4% 로 구성됩니다. 51.4% 급여 및 48.6% 보너스(회사 주식 및 옵션 포함). 는 $ 22.39K 가치에 해당하는 회사 주식의 0.67% 직접 소유합니다. 22.39K. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 2.8 년입니다.

주요 정보

Andrew Simpson

최고 경영자

US$300.0k

총 보상

CEO 급여 비율	100.0%
CEO 임기	2.6yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	3.1yrs

최근 관리 업데이트

Recent updates

HeartSciences granted U.S patent for ECG assessment of heart

Sep 20

Heart Test Laboratories reports Q1 results

Sep 13

CEO 보상 분석

Andrew Simpson 의 보수는 Heart Test Laboratories 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jul 31 2024	n/a	n/a	-US$7m
Apr 30 2024	US$300k	US$300k	-US$7m
Jan 31 2024	n/a	n/a	-US$6m
Oct 31 2023	n/a	n/a	-US$6m
Jul 31 2023	n/a	n/a	-US$6m
Apr 30 2023	US$456k	US$234k	-US$6m
Jan 31 2023	n/a	n/a	-US$7m
Oct 31 2022	n/a	n/a	-US$7m
Jul 31 2022	n/a	n/a	-US$6m
Apr 30 2022	US$145k	US$26k	-US$5m
Jan 31 2022	n/a	n/a	-US$4m
Apr 30 2021	US$43k	n/a	-US$2m
Apr 30 2020	US$50k	n/a	-US$4m

보상 대 시장: Andrew 의 총 보상 ($USD 455.94K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 683.56K ).

보상과 수익: Andrew 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Andrew Simpson (55 yo)

2.6yrs

테뉴어

US$300,000

보상

Mr. Andrew Simpson is Chairman and Chief Executive Officer of HeartSciences, Inc. Mr. Simpson serves as Chief Executive Officer of Heart Test Laboratories, Inc. since March 2022 and serves as its President...

리더십 팀

이름	위치	테뉴어	보상	소유권
Andrew Simpson	CEO, President & Chairman of the Board of Directors	2.6yrs	US$300.00k	0.48% $ 19.2k
Danielle Watson	CFO & Treasurer	2.5yrs	US$179.32k	0% $ 0
Mark Hilz	COO, Secretary & Director	2.6yrs	US$300.00k	0.49% $ 19.6k

2.6yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: HSCS 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Andrew Simpson	CEO, President & Chairman of the Board of Directors	12.3yrs	US$300.00k	0.48% $ 19.2k
Mark Hilz	COO, Secretary & Director	11.3yrs	US$300.00k	0.49% $ 19.6k
David Wells	Independent Director	1.8yrs	US$57.50k	0% $ 0
Bruce Bent	Independent Director	4.4yrs	US$60.00k	0.0019% $ 74.6
Brian Szymczak	Independent Director	10.8yrs	US$57.50k	0.0067% $ 267.8
Partho Sengupta	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Benjamin Glicksberg	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Jordan Strom	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: HSCS 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Heart Test Laboratories 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Heart Test Laboratories, Inc., Annual General Meeting, Nov 07, 2024

Heart Test Laboratories, Inc. Appoints Partho P. Sengupta to Its Scientific Advisory Board

Heart Test Laboratories, Inc. Appoints Jordan B. Strom to Its Scientific Advisory Board

HeartSciences Appoints Benjamin Glicksberg to its Scientific Advisory Board

Heart Test Laboratories, Inc., Annual General Meeting, Feb 15, 2024

Heart Test Laboratories, Inc., Annual General Meeting, Jan 17, 2024

Recent updates

Heart Test Laboratories, Inc., Annual General Meeting, Nov 07, 2024

Heart Test Laboratories, Inc. announced that it has received $1.9 million in funding

Heart Test Laboratories, Inc. Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

Nasdaq to Delist Heart Test Laboratories Securities from Nasdaq Capital Market

Nasdaq to Delist Heart Test Laboratories Securities from Nasdaq Capital Market

Forecast to breakeven in 2027

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Third quarter 2024 earnings released: US$0.031 loss per share (vs US$0.16 loss in 3Q 2023)

Heart Test Laboratories, Inc. Appoints Partho P. Sengupta to Its Scientific Advisory Board

Heart Test Laboratories, Inc. Appoints Jordan B. Strom to Its Scientific Advisory Board

HeartSciences Appoints Benjamin Glicksberg to its Scientific Advisory Board

Nasdaq Grants Extension to Heart Test Laboratories to Regain Compliance

Heart Test Laboratories, Inc., Annual General Meeting, Feb 15, 2024

Price target decreased by 77% to US$0.90

Heart Test Laboratories, Inc., Annual General Meeting, Jan 17, 2024

Heart Test Laboratories, Inc., Annual General Meeting, Jan 17, 2024

Heart Test Laboratories, Inc. announced that it has received $1.085006 million in funding

New major risk - Shareholder dilution

Heart Test Laboratories, Inc. announced that it has received $1 million in funding

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.28 loss in 1Q 2023)

Heart Test Laboratories, Inc. announced that it expects to receive $1 million in funding

Heart Test Laboratories Receives Decision from Panel Granting Company’s Request for Continued Listing on Nasdaq Capital Market, Subject to Company Demonstrating Compliance with Equity Rule on or Before November 21, 2023

Heart Test Laboratories, Inc. Announces Further Expansion of Artificial Intelligence Patent Portfolio

Heart Test Laboratories Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 9.2% to US$3.75

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 142%

Third quarter 2023 earnings released

Heart Test Laboratories, Inc. Announces Executive Changes

Heart Test Laboratories Receives Letter from the Nasdaq

Second quarter 2023 earnings released

Heart Test Laboratories, Inc.'s MyoVista Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events

Heart Test Laboratories, Inc. Receives Patent from the European Patent Office

Heart Test Laboratories, Inc. Announces Major Milestone with the Issuance of CPT Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction

Heart Test Laboratories, Inc. Granted U.S Patent for ECQ Assessment of Heart Diastolic Function Using Artificial Intelligence

HeartSciences granted U.S patent for ECG assessment of heart

Heart Test Laboratories, Inc. to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital

Heart Test Laboratories reports Q1 results

Heart Test Laboratories, Inc. has completed an IPO in the amount of $6.375 million.

Heart Test Laboratories, Inc. has completed an IPO in the amount of $6.375 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령